RxDoctor Payments DataLook up a doctor →

Sara Llerena, MD

General Practice · Miami, FLNPI 1487667994

Payments from drug & device makers

$6,324,891in general payments, 2019–2025

Across 668 payments — averaging $9468.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.7M
  • Astrazeneca UK Limited$1.3M
  • AstraZeneca$1.1M
  • Chiesi USA, Inc.$951K
  • GSK$488K
  • Esperion Therapeutics, Inc.$235K
  • plus $644K from 9 others
$1,932in research payments, 2019–2025

Across 3 payments — averaging $644.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,324,891 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$14,057
Medicare patients
25
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →